The trading price of Regulus Therapeutics Inc (NASDAQ:RGLS) closed higher on Tuesday, May 27, and closing at $7.91, 0.25% higher than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $8.20 and a 52-week low of $0.83. Over the past month, the stock has gained 186.59% in value.
Regulus Therapeutics Inc, whose market valuation is $547.64 million at the time of this writing, is expected to release its quarterly earnings report in June. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -0.18 per share this quarter, however they have predicted annual earnings per share of -0.78 for current year and -1.01 for next year.
On the technical side, indicators suggest RGLS has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned RGLS a recommendation rating is 1. Out of them, 0 rate it a Hold, while 1 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Regulus Therapeutics Inc (RGLS) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that RGLS’s price is currently 3.39% off the SMA20 and 89.87% off the SMA50. The RSI metric on the 14-day chart is currently showing 89.58, and weekly volatility stands at 0.27%. When measured over the past 30 days, the indicator reaches 19.35%. Regulus Therapeutics Inc (NASDAQ:RGLS)’s beta value is currently sitting at 0.37, while the Average True Range indicator is currently displaying 0.21. With analysts defining $7-$7 as the low and high price targets, we arrive at a consensus price target of $7 for the trailing 12-month period. The current price is about 11.5% off the estimated low and 11.5% off the forecast high, based on this estimate. Investors will be thrilled if RGLS’s share price rises to $7, which is the median consensus price. At that level, RGLS’s share price would be 11.5% above current price.
To see how Regulus Therapeutics Inc stock has been performing in comparison to its peers in the industry, here are the numbers: RGLS stock’s performance was 0.25% in the latest trading, and 311.98% in the past year.
An evaluation of the daily trading volume of Regulus Therapeutics Inc (NASDAQ:RGLS) indicates that the 3-month average is 1.90 million.
Currently, records show that 66.28 million of the company’s shares remain outstanding. The insiders hold 17.18% of outstanding shares, whereas institutions hold 68.23%. However, since the stock’s price has seen 400.63% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
